Varicella Laboratory Diagnosis and Management
Laboratory Diagnosis
PCR testing of skin lesion specimens (vesicles, scabs, or macular/papular lesions) is the gold standard for diagnosing varicella, with 95-100% sensitivity when collected at rash onset 1. For vaccine-modified cases, macular/papular lesions remain 100% sensitive 1.
Diagnostic Testing Algorithm:
Specimen Collection:
- First choice: Vesicle fluid or scab from skin lesions
- Alternative: Oral specimens (95-100% sensitive at rash onset for unmodified cases) 1
- Timing critical: Collect specimens at first visit when rash appears; yields drop dramatically after lesions resolve 1
Test Selection:
- PCR for VZV DNA: Preferred diagnostic method 1
- Direct fluorescent antibody (DFA): Alternative for antigen detection 2
- Serology (IgG): For immunity assessment only, NOT for acute diagnosis 3
- Avoid IgM testing: Not recommended for screening or diagnostic purposes despite being used in up to 11% of tests 3
Important caveat: Clinical diagnosis alone is 100% sensitive for unmodified varicella but only 85% sensitive for vaccine-modified cases, making laboratory confirmation increasingly important in the vaccination era 1.
Management by Patient Population
Immunocompromised Patients
Treat ALL immunocompromised patients with varicella immediately with acyclovir within 24 hours of rash onset 4. This has demonstrated effectiveness in reducing varicella-associated morbidity and mortality 4.
Dosing: Intravenous acyclovir (specific dosing per institutional protocols)
Healthy Children
Acyclovir is NOT routinely recommended for otherwise healthy children 4. The AAP determined that clinical benefits do not justify routine administration, as complications occur in only 1-2% of cases 4.
High-Risk Groups Requiring Treatment
Consider oral acyclovir for:
- Persons aged >12 years (adolescents and adults) 4
- Chronic cutaneous or pulmonary disorders 4
- Long-term salicylate therapy 4
- Short, intermittent, or aerosolized corticosteroid courses 4
- Secondary household contacts (some experts recommend) 4
Timing: Must initiate within 24 hours of rash onset for effectiveness 4. Acyclovir reduces duration of fever, number of days new lesions appear, and severity of symptoms 4.
Pregnant Women
For uncomplicated varicella: Routine oral acyclovir is NOT recommended due to unknown risks/benefits to fetus 4.
For serious complications (e.g., pneumonia): Consider intravenous acyclovir 4.
Safety profile: Category B drug; registry data from 596 first-trimester exposures showed birth defect rates approximating general population 4.
Post-Exposure Prophylaxis
VZIG (Varicella-Zoster Immune Globulin)
Administer VZIG to high-risk patients without evidence of immunity within 96 hours of exposure 4.
Dosing: 125 units/10 kg body weight, maximum 625 units (five vials), minimum 125 units 4.
Indications for VZIG:
- Immunocompromised patients without immunity
- Pregnant women without immunity
- Newborns whose mothers had varicella shortly before/after delivery
- Premature infants
- Patients on steroids >2 mg/kg or >20 mg/day prednisone equivalent 4
Special populations:
- Bone marrow transplant recipients: Consider nonimmune regardless of prior history 4
- Patients receiving monthly IGIV >400 mg/kg: Likely protected if last dose <3 weeks before exposure 4
Critical timing: Maximum benefit when given immediately after exposure; may be effective up to 96 hours 4. VZIG extends incubation period from 10-21 days to >28 days 4.
Vaccination Post-Exposure
For eligible patients without contraindications: Vaccination is the preferred method over acyclovir prophylaxis 4. Acyclovir is NOT indicated for prophylactic use in otherwise healthy individuals 4.
Evidence of Immunity
Acceptable evidence:
- Healthcare provider-diagnosed varicella (NOT parental/self-report alone) 4
- Laboratory confirmation of immunity
- Documentation of 2 doses of varicella vaccine
- U.S. birth before 1980 (EXCEPT for healthcare personnel, pregnant women, and immunocompromised persons) 4
Important limitation: Self-reported history in unvaccinated children aged 12 months-4 years has only 75% positive predictive value, compared to 89% in older children and 99-100% in adolescents/adults 4.